Bogart Wealth LLC Increases Stake in Pfizer Inc. $PFE

Key Points

• Bogart Wealth LLC increased its stake in Pfizer Inc. by 6.0% during the 2nd quarter, holding 411,159 shares valued at approximately $9.97 million.
• Pfizer recently reported earnings of $0.78 per share, exceeding estimates and demonstrating a 10.3% increase in revenue year-over-year.
• The company declared a quarterly dividend of $0.43 per share, resulting in a yield of 7.0%, with an ex-dividend date set for November 7th.

Bogart Wealth LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 6.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 411,159 shares of the biopharmaceutical company's stock after buying an additional 23,380 shares during the period. Bogart Wealth LLC's holdings in Pfizer were worth $9,966,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. purchased a new position in Pfizer during the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new position in Pfizer during the 1st quarter valued at about $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer during the 2nd quarter valued at about $29,000. Finally, Horizon Financial Services LLC purchased a new position in Pfizer during the 1st quarter valued at about $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.2%

NYSE:PFE opened at $24.52 on Monday. The company has a market cap of $139.38 billion, a PE ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.36. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company's 50 day moving average is $24.89 and its two-hundred day moving average is $24.11.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer's payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of research reports. UBS Group reissued a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday, October 10th. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.